不同剂量静脉注射人血免疫球蛋白治疗重症手足口病合并脑炎疗效分析

doi:10.3877/cma.j.issn.1673-5250.2013.02.018

目的

探讨3种不同剂量静脉注射人血免疫球蛋白(IVIG)治疗重症手足口病(HFMD)合并脑炎的疗效。

方法

选择2012年6月至2012年9月于本院就诊的75例重症HFMD合并脑炎患儿为研究对象，并按照随机抽签法分为A组(n＝25)，B组(n＝25)和C组(n＝25)(本研究遵循的程序符合本院人体试验委员会所制定的伦理学标准，得到该委员会批准，分组征得受试对象监护人的知情同意，并与之签署临床研究知情同意书)。3组患儿除均接受甘露醇、甲泼尼龙琥珀酸钠及对症支持治疗外，还分别接受不同剂量IVIG治疗，具体IVIG治疗方案：A组为1 g/(kg·d)×2 d，B组为500 mg/(kg·d)×2 d，C组为200 mg/(kg·d)×2 d。对3组患儿疗效进行比较。3组患儿年龄、病程、性别等比较，差异无统计学意义(P>0.05)。

结果

A组与B组和C组患儿疗效比较，差异均有统计学意义(P₁<0.05)。而B组和C组患儿疗效比较，差异无统计学意义(P₂>0.05)。

结论

大剂量IVIG治疗重症HFMD合并脑炎，能迅速改善临床症状、缩短病程、阻止病情进展及降低危重并发症发生率，具有较好疗效。

关键词: 静脉注射人血免疫球蛋白, 剂量, 手足口病, 重症, 脑炎

Objective

To explore the curative effect of different doses of intravenous immunoglobin(IVIG) in children with severe hand foot and mouth disease(HFMD) combined with encephalitis.

Methods

From June to September 2012, 75 children with severe HFMD combined with encephalitis were included in the study, and randomly divided into group A(n=25), group B(n=25)and group C(n=25). Besides mannitol, methylprednisolone and other supportive treatments, different doses of IVIG were given in three groups respectively. The curative effect was compared among three groups.The study protocol was approved by the Ethical Review Board of Investigation in Human Being of People's Hospital of Jimo.Informed consent was obtained from each parents. There was no significant difference in age, disease course and sex among three groups (P>0.05).

Results

There had significant differences in curative effect among three groups(P₁<0.05). There was no significant difference in curative effect between group B and group C(P₂>0.05).

Conclusions

High-dose IVIG was effective to children with severe HFMD combined with encephalitis, it can relief the symptoms quikly, shorten the course of the disease, avoid the progress of the disease and decrease the incidence rate of complications.

Key words: intravenous immunoglobin, dose, hand foot and mouth disease, severe case, encephalitis

表1 3组患儿一般资料比较(±s)

Table 1 Comparison of general condition among three groups(±s)

组别	n	性别[n(%)]		年龄(岁)	病程(d)
组别	n	男	女	年龄(岁)	病程(d)
A组	25	15(60.0)	10(40.0)	1.78±0.85	2.60±0.50
B组	25	12(48.0)	13(52.0)	1.92±1.21	2.48±0.51
C组	25	14(56.0)	11(44.0)	2.38±0.94	2.40±0.50
χ²/F		0.365		2.367	1.000
P		0.695		0.101	0.373

表1 3组患儿一般资料比较(±s)

Table 1 Comparison of general condition among three groups(±s)

组别	n	性别[n(%)]		年龄(岁)	病程(d)
组别	n	男	女	年龄(岁)	病程(d)
A组	25	15(60.0)	10(40.0)	1.78±0.85	2.60±0.50
B组	25	12(48.0)	13(52.0)	1.92±1.21	2.48±0.51
C组	25	14(56.0)	11(44.0)	2.38±0.94	2.40±0.50
χ²/F		0.365		2.367	1.000
P		0.695		0.101	0.373

表2 3组患儿临床疗效比较(h，±s)

Table 2 Comparison of clinical effect among three groups(h，±s)

组别	n	发热缓解时间	肢体抖动缓解时间	精神恢复时间	临床治愈时间	治疗无效患者数[n(%)]
A组	25	2.32±0.48	2.20±0.41	3.28±0.46	6.12±0.60	0(0.0)
B组	25	3.04±0.54	3.56±0.50	4.12±0.60	8.12±0.62	2( 8.0)
C组	25	3.08±0.57	3.68±0.45	4.20±0.65	8.52±0.65	6(24.0)
F/χ²		16.269	80.551	19.473	106.776	4.200
P₁		<0.01	<0.01	<0.01	<0.01	<0.05
t		0.253	0.881	0.419	1.089	1.445
P₂		0.802	0.387	0.679	0.083	0.163

表2 3组患儿临床疗效比较(h，±s)

Table 2 Comparison of clinical effect among three groups(h，±s)

组别	n	发热缓解时间	肢体抖动缓解时间	精神恢复时间	临床治愈时间	治疗无效患者数[n(%)]
A组	25	2.32±0.48	2.20±0.41	3.28±0.46	6.12±0.60	0(0.0)
B组	25	3.04±0.54	3.56±0.50	4.12±0.60	8.12±0.62	2( 8.0)
C组	25	3.08±0.57	3.68±0.45	4.20±0.65	8.52±0.65	6(24.0)
F/χ²		16.269	80.551	19.473	106.776	4.200
P₁		<0.01	<0.01	<0.01	<0.01	<0.05
t		0.253	0.881	0.419	1.089	1.445
P₂		0.802	0.387	0.679	0.083	0.163

[1]	Chen SC, Chang HL, Yan TR, et al.An eight-year study of epidemiologic features of enterovirus 71 infection in Taiwan[J]. Am J Trop Med Hyg, 2007, 77(1):188-191.
[2]	Wang SM, Liu CC. Enterovirus 71:Epidemiology, pathogenesis and management[J]. Expert Rev Anti Infect Ther, 2009, 7(6):735-742.
[3]	Ministry of Health of the People's Republic of China.Diagnosis and treatment guideline on hand-foot-mouth disease(2010)[J]. Int J Respir, 2010, 30(24):1473-1475.
[4]	Ministry of Health of the People's Republic of China.Diagnosis and treatment guideline on hand-foot-mouth disease(2008)[J]. Herald Med, 2009, 28(3):404-406.
[5]	Cao DZ, Fu D, He YX, et al. Clinical features of 80 severe cases of hand-foot-mouth disease of Shenzhen in 2008[J].Chin Pediatr Emerg Med, 2009, 16(2):145-148.
[6]	Nolan MA, Craig MM, Lahra MM, et al.Survival after pulmonary edema due to enterovirus 71 encephalitis[J]. Neurology, 2003, 60:1651-1656.
[7]	Du CQ, Wu Q, Wang MF, et al.Etiological study and clinical treatment in children with hand foot and mouth disease[J/CD].Chin J Obstet Gynecol Pediatr:Electron Ed, 2012, (1):60-63.
[8]	Lin TY, Chang LY, Huang YC, et al.Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infection:Implicalions for early recognition and therapy[J].Acta Paediatr, 2002, 91(6):632-635.
[9]	Liu YX, Zhou BP. New progress on hand, foot and mouth disease caused by enterovirus 71[J/CD].Chin J Exp Clin Infect Dis: Electron Ed, 2010, 4(1):71-75.
[10]	Chen DY, Huang XW. Analysis on testing serum immunoglobulins and hs-CRP in children with hand-foot-mouth disease[J]. Chin Gener Pract, 2011, 14(2):476-477.
[11]	Du BY, Bai L, Shen Y, et al. The effects of enterovirus 71 infection on the ability of t cellular immunity[J].J Med Res, 2010, 39(8):50-53.
[12]	Chen XN. Theoretical guidance on diagnosis and treatment of severe virus infectious disease with SIRS/sepsis according to the hand, foot and mouth disease[J]. Chin Pediatr Emerg Med, 2010, 17(1):87-88.
[13]	Cao RY, Han JF, Qin E, et al. Mechanism of intravenous immunoglobulin therapy for severe hand-foot-mouth disease:A review[J]. Chin J Biotechnol, 2011, 27(5):712-716.
[14]	Cao R, Han J, Deng Y, et al.Presence of high-titer neutralizing antibodies against enterovirus 71 in intravenous immunoglobin manufactured from Chinese donors[J].Clin Infect Dis, 2010, 50(1):125-126.
[15]	Kaneko Y, Nimmerjahn F, Ravetch JV.Anti-inflammatory activity of immunoglobin G resulting from Fc sialylation[J].Science, 2006, 313(5787):670-673.
[16]	Hemming VG.Use of intravenous immunoglobin for prophylaxis or treatment of infectious diseases[J].Clin Diagn Lab Immunol, 2001, 8(5):859-863.
[17]	Mouthon L, Lortholary O. Intravenous immunoglobins in infectious diseases:Where do we stand[J]？Clin Microbiol Infect, 2003, 9(5):333-338.
[18]	Wang SM, Lei HY, Huang MC, et al.Modulation of cytokine production by intravenous immunoglobin in patients with enterovirus 71-associated brainstem encephalitis[J].J Clin Virol, 2006, 37(1):47-52.
[19]	Wang SM, Ho TS, Shen CF, et al. Enterovirus 71, one virus and many stories[J].Pediatr Neonatol, 2008, 49(4):113-115.

[1]	徐娟, 孙汝贤, 赵东亚, 张清艳, 金兆辰, 蔡燕. 右美托咪定序贯镇静模式对中深度镇静的机械通气患者预后和谵妄的影响[J]. 中华危重症医学杂志(电子版), 2023, 16(05): 363-369.
[2]	尹朱丹, 王昱, 镇坷, 许彬, 田雅丽, 童孜蓉. 早期低热量肠内营养对危重症患者预后影响的Meta分析[J]. 中华危重症医学杂志(电子版), 2023, 16(03): 215-222.
[3]	张伟, 王莉, 安彩霞, 王俭勤. 不同辐射防护措施对降低儿童先天性心脏病介入诊疗过程中辐射剂量的应用价值[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 455-463.
[4]	黄翠君, 张喜玲, 刘思嘉, 刘云建. 重症急性胰腺炎营养支持治疗研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(05): 385-390.
[5]	彭文翰. 肾移植受者早期霉酚酸强化剂量长期有效性和安全性的研究[J]. 中华移植杂志(电子版), 2023, 17(05): 0-.
[6]	江文诗, 何湘湘. 全球及我国器官捐献发展特征分析与学科建设[J]. 中华移植杂志(电子版), 2023, 17(05): 280-286.
[7]	周子健, 吴忠. CT在泌尿系结石诊疗中的应用进展[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(03): 299-302.
[8]	陈秀山, 张婷婷, 杨栓盈, 高娜. 低剂量CT扫描在肺部同轴穿刺活检中的临床应用[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 587-588.
[9]	王小红, 钱晶, 翁文俊, 周国雄, 朱顺星, 祁小鸣, 刘春, 王萍, 沈伟, 程睿智, 秦璟灏. 巯基丙酮酸硫基转移酶调控核因子κB信号介导自噬对重症急性胰腺炎大鼠的影响及机制[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 422-426.
[10]	马强, 李军, 苟丽娟. 重症急性胰腺炎miR-21-3p、RUNX3表达水平及对病情发展程度的预测[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 337-341.
[11]	李琪, 黄钟莹, 袁平, 关振鹏. 基于某三级医院的ICU多重耐药菌医院感染影响因素的分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 777-782.
[12]	邱学荣, 张秀琴, 张欢, 刘婷, 高翠琴. 动态监测SAA给予抗生素在电子支气管镜联合普米克令舒治疗重症肺炎中的价值研究[J]. 中华临床医师杂志(电子版), 2023, 17(03): 308-313.
[13]	张小玉, 郭伟, 吴秀丽, 汪蕊, 汪莹. ICU专科护士培训大纲的构建和应用[J]. 中华临床医师杂志(电子版), 2023, 17(03): 330-334.
[14]	刘平娟, 罗科城, 吴家茵, 廖康, 胡雯雯, 陈怡丽. 神经内科重症监护室患者肠道耐碳青霉烯类肠杆菌目细菌主动筛查研究[J]. 中华临床实验室管理电子杂志, 2023, 11(04): 235-240.
[15]	韩优, 郝婧, 董红霞, 戴丽, 周保硕, 高慧贤. 经鼻空肠营养管在急性重症胰腺炎的早期应用及护理方法分析[J]. 中华胃肠内镜电子杂志, 2023, 10(04): 274-277.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Curative Effect Analysis of Different Doses of Intravenous Immunoglobin for Children With Severe Hand Foot and Mouth Disease Combined With Encephalitis

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Curative Effect Analysis of Different Doses of Intravenous Immunoglobin for Children With Severe Hand Foot and Mouth Disease Combined With Encephalitis